As device-makers, healthcare practitioners and people with diabetes convened at this year’s annual meeting of the American Diabetes Association, one major theme emerged: the industry is catching on to the potential of closed-loop insulin delivery systems.
Major medical technology companies, including Medtronic and Insulet, touted data at this year’s meeting demonstrating the benefits of their systems that connect glucose monitoring data and insulin dosing. Patient advocacy groups, like the JDRF, have called on the industry to fund and develop automated insulin delivery systems – echoing the calls of a community of people with diabetes that have already been doing this themselves.
Industry players seem to have taken the hint from the diabetes community. Here’s a look at what they’re working on.
NEXT: Medtronic touts real-world outcomes for MiniMed 670G
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn
I am an omnipod user. Just talked to their customer service representative, who knows of no plans to connect a CGMS to an Omnipod.
Has Insulet’s Omnipod Eros, https://www.drugdeliverybusiness.com/insulet-settles-shareholder-suit-over-omnipod-eros-device/, kept Insulet from pursuing a closed loop system?
‘Insulet, touted data at this year’s meeting demonstrating the benefits of their systems that connect glucose monitoring data and insulin dosing’
Hi Carolyn, thanks for your message! Insulet is developing a system, called the Omnipod Horizon, that is designed to automate insulin delivery. Here’s some more information from Insulet’s CEO: https://www.drugdeliverybusiness.com/how-insulets-ceo-plans-to-create-a-billion-dollar-business/